BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24260886)

  • 1. [Methods of detection and prognostic significance of genetic material increase of the short arm of chromosome 2 and a deletion of the short arm of chromosome 1 in patients with neuroblastoma].
    Druĭ AE; Tsaur GA; Shorikov EV; Popov AM; Plekhanova OM; Typonogov SN; Savel'ev LI; Tsvirenko SV; Fechina LG
    Vopr Onkol; 2013; 59(5):591-8. PubMed ID: 24260886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.
    Boensch M; Oberthuer A; Fischer M; Skowron M; Oestreich J; Berthold F; Spitz R
    Diagn Mol Pathol; 2005 Sep; 14(3):177-82. PubMed ID: 16106200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Detection of Genetic Parameters for Prognostic Stratification of Neuroblastoma Using Multiplex Ligation-Dependent Probe Amplification Technique.
    Tumer S; Altungoz O; Bagci O; Olgun HN
    Genet Test Mol Biomarkers; 2016 Feb; 20(2):74-80. PubMed ID: 26790040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification.
    Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A
    J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.
    Berbegall AP; Villamón E; Piqueras M; Tadeo I; Djos A; Ambros PF; Martinsson T; Ambros IM; Cañete A; Castel V; Navarro S; Noguera R
    Oncogene; 2016 Mar; 35(11):1423-32. PubMed ID: 26119945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.
    Simon T; Spitz R; Faldum A; Hero B; Berthold F
    J Pediatr Hematol Oncol; 2004 Dec; 26(12):791-6. PubMed ID: 15591897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma.
    Souzaki R; Tajiri T; Teshiba R; Higashi M; Kinoshita Y; Tanaka S; Taguchi T
    Pediatr Surg Int; 2011 Mar; 27(3):231-6. PubMed ID: 21046119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
    Bown N; Lastowska M; Cotterill S; O'Neill S; Ellershaw C; Roberts P; Lewis I; Pearson AD;
    Med Pediatr Oncol; 2001 Jan; 36(1):14-9. PubMed ID: 11464868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics.
    Jeison M; Ash S; Halevy-Berko G; Mardoukh J; Luria D; Avigad S; Feinberg-Gorenshtein G; Goshen Y; Hertzel G; Kapelushnik J; Ben Barak A; Attias D; Steinberg R; Stein J; Stark B; Yaniv I
    Am J Pathol; 2010 Jun; 176(6):2616-25. PubMed ID: 20395439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.
    Weber A; Imisch P; Bergmann E; Christiansen H
    J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization.
    Scaruffi P; Parodi S; Mazzocco K; Defferrari R; Fontana V; Bonassi S; Tonini GP
    Mol Diagn; 2004; 8(2):93-100. PubMed ID: 15527323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR.
    Anderson J; Gibson S; Williamson D; Rampling D; Austin C; Shipley J; Sebire N; Brock P
    Pediatr Blood Cancer; 2006 Jun; 46(7):820-4. PubMed ID: 16220551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk estimation of neuroblastoma patients using molecular markers.
    Fischer M; Spitz R; Oberthür A; Westermann F; Berthold F
    Klin Padiatr; 2008; 220(3):137-46. PubMed ID: 18478485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of chromosome 1p loss of heterozygosity in neuroblastoma.
    Maris JM; White PS; Beltinger CP; Sulman EP; Castleberry RP; Shuster JJ; Look AT; Brodeur GM
    Cancer Res; 1995 Oct; 55(20):4664-9. PubMed ID: 7553646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of MYCN amplification and 1p deletion in neuroblastomas with high tumor vascularity.
    Ozer E; Altungoz O; Unlu M; Aygun N; Tumer S; Olgun N
    Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):181-6. PubMed ID: 17525631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of MYCN amplification status in Tunisian neuroblastoma: CISH and MLPA combining approach.
    H'Mida Ben Brahim D; Trabelsi S; Chabchoub I; Gargouri I; Harrabi I; Moussa A; Chourabi M; Haddaji M; Sassi S; Mougou S; Gribaa M; Ben Ahmed S; Zakhama A; Nouri A; Saad A
    Tunis Med; 2015; 93(8-9):527-31. PubMed ID: 26815518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 8q deletion in MYCN-amplified neuroblastoma of a child born from assisted reproductive technology.
    Brassesco MS; Valera ET; de Oliveira FM; de Paula Queiroz RG; Scrideli CA; Sakamoto-Hojo ET; Tone LG
    J Pediatr Hematol Oncol; 2009 Mar; 31(3):215-9. PubMed ID: 19262252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
    Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
    J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.